TRThalia Robakis

Thalia Robakis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thalia Robakis has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic architecture of postpartum psychosis: from common to rare genetic variation

    by Seulgi Jung, Madison Caballero, Adrianna KęPińska, Shelby Smout, Trine Munk-Olsen, Thalia K. Robakis, Veerle Bergink, Behrang Mahjani

    Postpartum psychosis is a severe psychiatric condition marked by the abrupt onset of psychosis, mania, or psychotic depression following childbirth. Despite evidence for a strong genetic basis, the roles of common and rare genetic variation remain poorly understood. Leveraging data from Swedish national registers and genomic data from the All of Us Research Program, we estimated family-based heritability at 55% and whole-genome sequencing-based heritability at 46%. Rare coding variant analysis identified HMGCR as a gene in which rare damaging variants confer risk for postpartum psychosis (FDR < 0.05). Analyses of 240,009 participants from the All of Us Research Program and 58,990 participants from the Mount Sinai BioMe Biobank identified significant associations linking deleterious rare variants in HMGCR to vascular dementia and mental disorder, not otherwise specified, supporting the gene’s broader psychiatric relevance. Additionally, among the top 200 genes ranked by association statistics, 17% of bipolar disorder, 21% of schizophrenia, and 16–25% of multiple autoimmune disorders exhibit a possible association with postpartum psychosis. These findings reveal unique genetic contributions and shared pathways, providing a foundation for understanding pathophysiology and advancing therapeutic strategies.


  • Top Cited Papers
    Open Access

    Association of parental prenatal mental health with offspring neurodevelopmental disorders: a systematic review and meta-analysis

    by Adrianna Kępińska, Thalia Robakis, Shelby Smout, Rachel Bercovitch, Lily Cohen, Ingrid Christina Gustavsson Mahjani, Alkistis Skalkidou, Veerle Bergink, Behrang Mahjani

    Background: Parental prenatal mood and anxiety disorders (PMADs) are linked to child neurodevelopmental disorders (NDDs), but evaluations of the magnitude and mechanisms of this association are limited. This study estimates the strength of the association and whether it is impacted by genetic and environmental factors. Methods: A systematic search of PubMed, CENTRAL, PsycINFO, OVID, and Google Scholar was performed for articles published from January 1988 to September 2025. Of 2,420 articles screened, 74 met the inclusion criteria. Meta-analyses were conducted on 21 studies, and 53 were included in the narrative synthesis. We conducted random-effects meta-analyses, along with tests for heterogeneity ( I 2 ) and publication bias (Egger’s test). The review followed PRISMA and MOOSE guidelines. Results: Maternal PMADs were associated with a significantly increased risk of attention-deficit/hyperactivity disorder (ADHD; odds ratio [OR] 1.91, 95% confidence interval [CI] 1.45–2.52) and autism spectrum disorder (ASD; OR 1.75, 95% CI 1.43–2.14) in children. Paternal PMADs were also associated with the risk of NDDs, with combined odds for ASD and ADHD (OR = 1.23, 95% CI 1.14–1.33). Several studies suggested that the link between parental PMADs and offspring NDDs might be impacted by both genetic and environmental factors, including the impact of ongoing parental depression on child behavior. Conclusions: Parental PMADs are associated with increased risk of NDDs in children. These findings likely reflect a combination of inherited liability and environmental processes; clarifying mechanisms will require genetically informed designs. Regardless of mechanism, offering optional, family-centered developmental support may help promote child well-being in families where a parent is experiencing PMADs.


  • Open Access

    Correction: Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide

    by Veerle Bergink, Mariella Suleiman, Mary-Anne Hennen, Thalia Robakis

  • Open Access

    Management of Bipolar Disorder in Pregnancy and Postpartum: A Clinicians’ Guide

    by Veerle Bergink, Mariella Suleiman, Mary-Anne Hennen, Thalia Robakis

    Medication management in women with bipolar disorder (BD) in the perinatal period is challenging, given that many patients taper or stop medication during pregnancy, and the postpartum period is an extremely high-risk period for relapse. The objective of this narrative review was to investigate the perinatal efficacy as well as potential adverse effects on the child of common treatments for bipolar disorder. These treatments include lithium, lamotrigine, other antiepileptics, quetiapine, olanzapine, aripiprazole, other antipsychotics, antidepressants, benzodiazepines, Z-drugs, and other sleep medication. Despite the worldwide decline in lithium use, it remains the gold standard for acute and maintenance treatment of BD, and we continue to advise its use in women of reproductive age. In contrast, medications with a high risk for teratogenicity such as valproate and carbamazepine should be avoided in women of childbearing potential. Women with bipolar disorder are at very high risk of relapse after delivery, but this risk is more than twofold lower with adequate pharmacological prophylaxis. We advise to make a written perinatal bipolar relapse prevention plan in collaboration with the patient, family, and healthcare professionals, which includes a description of: (1) maintenance treatment during pregnancy, (2) preferred mode of delivery, (3) medication immediately after delivery and the first months postpartum for relapse prevention, (4) preferred plan for feeding (breast-feeding versus bottle-feeding), (5) strategies to assist women in ensuring adequate sleep and stable circadian rhythm in the first weeks after delivery, and (6) how to recognize the first symptoms of relapse and which intervention strategies to take.


  • Open Access

    Systematic Review: Antipsychotic Medication in Pregnancy and Neurodevelopmental Outcomes in Children

    by Carly A. Kaplan, Eline M.P. Poels, Marion I. van Den Heuvel, Hilmar H. Bijma, Veerle Bergink, Anna-Sophie Rommel, Thalia Robakis


  • Open Access

    Identifying postpartum depression: Using key risk factors for early detection

    by Mette-Marie Zacher Kjeldsen, Kathrine Bang Madsen, Xiaoqin Liu, Merete Lund Mægbæk, Thalia Robakis, Veerle Bergink, Trine Munk-Olsen

    Background Personal and family history of psychiatric disorders are key risk factors for postpartum depression (PPD), yet their combined contribution has been understudied. Objective To examine personal and family psychiatric history, alone and combined, and their effect on absolute risk and relative risk (RR) of mild/moderate or severe PPD. Methods In this cohort study, we used data from 142 064 childbirths with PPD screenings from 2015 to 2021 merged with population registers. Exposures were personal and family psychiatric history defined as a psychiatric hospital contact or psychotropic prescription fills by index mothers and their parents prior to delivery. Outcomes were mild/moderate PPD (Edinburgh Postnatal Depression Scale, cut-off: ≥11 within 12 weeks post partum) and severe PPD (antidepressant fill or depression diagnosis within 6 months post partum). We calculated absolute risks and RRs using Poisson regression models adjusted for parity, education, maternal age, and calendar year. Findings Of the 142 064 participants, 23.4% had no psychiatric history, 47.4% had only family history, 6.0% had only personal history, and 23.2% had both. The latter group had the highest risk of PPD: absolute risk of mild/moderate PPD was 11.7% (95% CI 11.5%; 11.8%), and adjusted RR: 2.35 (95% CI 2.22; 2.49). Alone, personal psychiatric history was the most potent risk factor. Dose–response relationship based on severity of personal and family psychiatric history was found. Discussion Our study documents a substantial association between personal and family psychiatric history and PPD risk. Clinical implications Evaluating combinations of risk factors is important to improve risk assessment.


  • Attachment classification and early adversity predict perinatal partial hospital treatment response

    by Annie Hart, Naomi Weiss-Goldman, Jennifer Halpern, Felicity Bennett, Lindsay A. White, Catherine Birndorf, Nicole Van Nortwick, Lauren M. Osborne, Thalia K. Robakis


  • Outcomes at the Motherhood Center: A Comparison of Virtual and On-Site Versions of a Specialized Perinatal Partial Hospitalization Program

    by Jeana DeMairo, Liza Rimsky, Ada Moses, Catherine Birndorf, Paige Bellenbaum, Nicole Van Nortwick, Lauren M. Osborne, Thalia K. Robakis

    Objectives Remotely administered mental health care is becoming increasingly common for treatment of a range of psychiatric disorders; however, there is a dearth of literature overviewing direct comparisons between remote and in-person interventions for treatment of Perinatal Mood and Anxiety Disorders (PMADs). The sudden advent of the Covid-19 pandemic in New York City forced an abrupt conversion for an intensive day treatment program for new mothers with PMADs, from an on-site to a remote program. Methods The current report compares outcomes of 81 women who completed the program in-person to those of 60 women who completed the program remotely. Results Improvement in depression scores was statistically superior in the remote program, and improvement in mother-infant bonding was statistically equivalent between the on-site and remote programs. Discussion These findings indicate that specialized partial hospitalization treatment for individuals with moderate to severe psychiatric illness can be effectively provided via telehealth, thus offering improved convenience, accessibility, and safety without compromising care. We conclude that remotely administered group psychotherapy is an effective intervention for women with moderate to severe PMADs.


  • Faculty Opinions recommendation of Depression associated with hormonal contraceptive use as a risk indicator for postpartum depression.

    by Thalia Robakis

    While reproductive events, including the menstrual cycle, hormonal contraceptive use, and the perinatal period, have long been associated with mental health risks, it remains unclear whether there is a single underlying reproductive psychiatric susceptibility associated with all of these, or if they represent distinct pathophysiological categories. Larsen et al. now provide the most reliable evidence to date for the former of these possibilities. This group analyzed all women in Denmark born after 1978 who delivered a child by 2017. They determined whether the onset of a depressive episode within 6 months of starting hormonal contraception was associated with an increased likelihood of a depressive episode within 6 months postpartum. They found evidence for a moderately strong association, with women who had prior contraceptive-associated depression at 1.42x higher odds for a postpartum depressive episode. This paper is particularly useful in that it allows for the first time an estimate of the relative prevalences of hormonally-associated versus non-hormonally associated depressive episodes. It has been hypothesized for some time that the hormonally-associated represent a subset of all perinatal depressive episodes, but solid numbers on the size of this subset have been lacking. Information from Larsen et al.'s Table 2 suggests that women with a psychiatric vulnerability to hormonal contraception may constitute about 3% of the population but account for about 24% of all women with non-perinatal depressive episodes, and furthermore that about 30% of all perinatal depressive episodes occurred in women with such a hormonally responsive psychiatric diathesis. Furthermore, Larsen et al. also confirm existing risk factors for perinatal depressive episodes, including personal and family psychiatric history, young parenthood, and low level of education, and allow a comparison of the relative risk weights conferred by each of these in comparison to the risk conferred by hormonal susceptibility. This information will be extremely helpful for researchers attempting to untangle the distinct pathophysiological pathways contributing to reproductive episodes of depression. It may also be helpful clinically for both clinicians and patients to gauge personal risk for postpartum depression.

  • In utero exposure to ADHD medication and long-term offspring outcomes

    by Kathrine Bang Madsen, Thalia K. Robakis, Xiaoqin Liu, Natalie Momen, Henrik Larsson, Julie Werenberg Dreier, Helene Kildegaard, Jane Bjerg Groth, Jeffrey H. Newcorn, Per Hove Thomsen, et al.

    Attention Deficit Hyperactivity Disorder (ADHD) medication is increasingly being used during pregnancy. Concerns have been raised as to whether ADHD medication has long-term adverse effects on the offspring. The authors investigated whether in utero exposure to ADHD medication was associated with adverse long-term neurodevelopmental and growth outcomes in offspring. The population-based cohort study in the Danish national registers included 1,068,073 liveborn singletons from 1998 to 2015 followed until any developmental diagnosis, death, emigration, or December 31, 2018. Children of mothers who continued ADHD medication (methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) during pregnancy and children of mothers who discontinued ADHD medication before pregnancy were compared using Cox regression. Main outcomes were neurodevelopmental psychiatric disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment during childhood or adolescence. In total, 898 children were exposed to ADHD medication during pregnancy compared to 1270 children whose mothers discontinued ADHD medication before pregnancy. After adjustment for demographic and psychiatric characteristics of the mother, no increased risk of any offspring developmental disorders was found combined (aHR 0.97, 95% CI 0.81 to 1.17) or for separate subcategories. Similarly, no increased risk was found for any sub-categories of outcomes in the negative control or sibling controlled analyses. Neurodevelopment and growth in offspring do not differ based on antenatal exposure to ADHD medication. These findings provide reassurance for women with ADHD who depend on ADHD medication for daily functioning and who consider continuing medication in pregnancy.